BlinkLab (ASX:BB1) said the North Shore Pediatric Therapy joined its US clinical study, and it is expected to enroll patients in the coming weeks, according to a Monday Australian bourse filing.
As part of the US registrational study, North Shore's use of the ADOS-2 diagnostic tool will serve as a critical benchmark for standard-of-care comparisons, the filing said.
North Shore, a provider of pediatric services, specializing in the evaluation and treatment of autism, is the second US-based site to join the 100-patient initial phase of the registrational study.
The clinic also provides access to a diverse population of children throughout the Chicago area, ensuring the study reflects a broad range of backgrounds and developmental profiles.
The firm's shares rose 8% on market close on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.